Objectives: This retrospective observational study evaluated the distribution of dense breasts by age group among healthy Korean women.
Methods: Participants were women aged 30 years and older who voluntarily underwent screening mammography between January 2007 and December 2011. Women who received the Breast Imaging Reporting and Data System for mammographic density of 3 or 4 were defined as having dense breasts. The proportion of women with dense breasts (PDB, %) was calculated by dividing the number of participants with dense breasts by the total number of participants.
Results: Among the 231,058 women who participated, 78.15% were classified as having dense breasts. PDB was highest in the youngest age group (PDB=94.87%) and lowest in the oldest age group. The greatest difference in PDB between adjacent age groups was observed in the group aged 60-64 years.
Conclusions: The results show that the proportion of dense breasts by age group increased in all age groups, except in those aged 35-39 years. These findings suggest an association between the age distribution of dense breasts and trends in breast cancer incidence. Further studies are needed to estimate the change in breast cancer incidence rate by age and the accumulation of fatty breast tissue in Korean women.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258717 | PMC |
| http://dx.doi.org/10.4178/epih/e2014027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Early Recurrence of Triple Negative Breast Cancer with Pathological Complete Response Following Neoadjuvant Chemotherapy and a Poor Prognosis-A Case Report].
Gan To Kagaku Ryoho
December 2024
Breast Center, Kochi Medical School Hospital.
In this study, we report the case of a patient with triple-negative breast cancer who achieved a pathological complete response(pCR)following neoadjuvant chemotherapy but experienced early recurrence and had a poor prognosis. A 46-year-old woman with a diagnosis of triple-negative breast cancer(cT2cN3cM0, cStage ⅢC)received neoadjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide, followed by weekly paclitaxel. The patient underwent a mastectomy and axillary lymph node dissection, achieving pCR.
View Article and Find Full Text PDFAssociations between breastfeeding and breast cancer risk through mammographic breast density in a cohort of Korean women.
Int J Epidemiol
December 2024
Department of Preventive Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.
Background: Mammographic breast density has been suggested to play a role as a mediator between the risk factors for breast cancer (BC) and BC risk. We investigated the extent to which never breastfeeding is a risk factor for BC and how this risk is further mediated by increased mammographic breast density.
Methods: This retrospective cohort study included 4 136 723 women aged ≥40 years who underwent mammographic screening between 2009 and 2010 and were followed up until 31 December 2020.
The "Pfizer Boob Job": A Case of Unexplained Gigantomastia.
Plast Reconstr Surg Glob Open
December 2024
From the Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
True parenchymal breast changes following COVID-19 vaccination are exceedingly rare. Equally rare are incidences of pseudoangiomatous stromal hyperplasia (PASH)-associated gigantomastia. The patient in this case report presented with both occurrences and experienced massive breast enlargement 1 week postadministration of the Pfizer/BioNTech COVID-19 vaccine, which worsened after her second dose.
View Article and Find Full Text PDFInfluence of BI-RADS Breast Density Scores on the Implementation of Supplemental Imaging Modalities in Those With Average Risk and Negative Mammogram by Primary Care Providers in British Columbia.
Can Assoc Radiol J
December 2024
Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Breast Imaging-Reporting and Data System (BI-RADS) density scores have been included in screening mammography reports in BC since 2018. Despite these density scores being present in screening mammography reports for numerous years, there remains insufficient evidence to guide supplemental testing for patients with dense breasts. The primary objective of this study was to evaluate how primary care providers in Canada utilize BI-RADS density scores reported on normal screening mammograms of average risk, asymptomatic patients in their clinical practice.
View Article and Find Full Text PDFBenefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.
Lancet Reg Health Eur
February 2025
Karolinska Institutet, Oncology/Pathology Department, Stockholm, Sweden.
Background: It is unclear whether some patients with high-risk breast cancer do not warrant adjuvant dose-dense chemotherapy due to small expected absolute benefit.
Methods: The phase 3 PANTHER trial (NCT00798070) compared adjuvant sequential epirubicin/cyclophosphamide (EC) and docetaxel (D) administered in either tailored dose-dense (tDD EC/D) or standard interval schedule (FEC/D) to patients with high-risk resected early breast cancer (n = 2003). We compared outcomes across key subgroups of interest, evaluated the performance of the online prognostication and treatment benefit estimation tool PREDICT and conducted a subpopulation treatment effect pattern plot (STEPP) analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!